英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
neia查看　neia　在百度字典中的解释百度英翻中〔查看〕
neia查看　neia　在Google字典中的解释Google英翻中〔查看〕
neia查看　neia　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
    Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for
  • Lost in translation: Revisiting the use of tyrosine kinase . . .
    Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment
  • Zanzalintinib Atezolizumab Improves CRC Survival, Expands TKI . . .
    New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options
  • High-dose short-term osimertinib treatment is effective in . . .
    Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC) To leverage the additional lower-affinity targets that most TKIs have, high-dose
  • Multi-omics characterization of response to tyrosine kinase . . .
    Multi-omics characterization of response to tyrosine kinase inhibitor plus immunotherapy in MSS pMMR metastatic colorectal cancer: A multicenter biomarker study If you have the appropriate software installed, you can download article citation data to the citation manager of your choice
  • Fruquintinib as new treatment option in metastatic colorectal . . .
    Introduction Available treatments for colorectal cancer are limited However, in the last few years several advances and new treatment options became available and expanded the continuum of care in metastatic colorectal cancer (mCRC)
  • Abstract 6002: Tyrosine kinase inhibitor (TKI) plus PD-1 . . .
    Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS pMMR metastatic colorectal adenocarcinoma (mCRC): Results of a multicenter, phase II trial (TRAP) [abstract] In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL
  • Frontiers | A multi-center effectiveness comparison study of . . .
    A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
  • RETRACTED ARTICLE: Rechallenge therapy versus tyrosine kinase . . .
    Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy
  • Immune checkpoint inhibitor in third-line treatment of . . .
    I is a beneficial addition to third-line treatment for some MSS mCRC patients, providing improved survival benefit and controllable safety, and a directional OS improvement Background The third-line treatment options recommended by guidelines for metastatic colorectal cancer (mCRC) are limited with unsatisfactory efficacy Immune checkpoint inhibitor (ICI)-based strategies have been





中文字典-英文字典  2005-2009